Success Metrics

Clinical Success Rate
88.9%

Based on 8 completed trials

Completion Rate
89%(8/9)
Active Trials
0(0%)
Results Posted
25%(2 trials)
Terminated
1(9%)

Phase Distribution

Ph phase_1
4
36%
Ph phase_2
3
27%
Ph phase_3
4
36%

Phase Distribution

4

Early Stage

3

Mid Stage

4

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
4(36.4%)
Phase 2Efficacy & side effects
3(27.3%)
Phase 3Large-scale testing
4(36.4%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

80.0%

8 of 10 finished

Non-Completion Rate

20.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(8)
Terminated(2)
Other(1)

Detailed Status

Completed8
Terminated1
Withdrawn1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
88.9%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (36.4%)
Phase 23 (27.3%)
Phase 34 (36.4%)

Trials by Status

completed873%
terminated19%
withdrawn19%
unknown19%

Recent Activity

0 active trials
Showing 5 of 11
completedphase_3

Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

NCT03250338
completedphase_3

Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML

NCT03258931
completedphase_2

A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations

NCT02283177
completedphase_1

Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML

NCT02626338
terminatedphase_3

Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations

NCT02298166
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT03250338Phase 3

Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

Completed
NCT03258931Phase 3

Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML

Completed
NCT02283177Phase 2

A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations

Completed
NCT02626338Phase 1

Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML

Completed
NCT02298166Phase 3

Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations

Terminated
NCT02847429Phase 3

Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST

Unknown
NCT02626364Phase 2

Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification

Completed
NCT03193918Phase 1

Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma

Completed
NCT03324243Phase 2

A Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia

Withdrawn
NCT02270788Phase 1

Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies

Completed
NCT01393912Phase 1

PDGFR Inhibitor Crenolanib in Children/Young Adults With Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade Glioma

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11